European guidelines on managing adverse effects of medication for ADHD
- PMID: 21042924
- PMCID: PMC3012210
- DOI: 10.1007/s00787-010-0140-6
European guidelines on managing adverse effects of medication for ADHD
Abstract
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
Figures
References
-
- (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073–1086 - PubMed
-
- (2001) Methylphenidate and narcolepsy: new indication. When modafinil fails. Prescrire Int 10:7–9 - PubMed
-
- (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536 - PubMed
-
- (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical